《健康元：健康元药业集团股份有限公司2022年第一季度报告（英文版）.PDF》由会员分享，可在线阅读，更多相关《健康元：健康元药业集团股份有限公司2022年第一季度报告（英文版）.PDF（16页珍藏版）》请在taowenge.com淘文阁网|工程机械CAD图纸|机械工程制图|CAD装配图下载|SolidWorks_CaTia_CAD_UG_PROE_设计图分享下载上搜索。
1、Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report 1 / 16 Stock code：600380 Stock abbreviation：健康元 Joincare Pharmaceutical Group Industry Co., Ltd 2022 First Quarterly Report Board of Directors (the “Board”) and all Directors of the Company hereby warrant that there are no
2、false representations, misleading statements or material omissions contained in this report, and severally and jointly accept responsibility for the truthfulness, accuracy and completeness of the contents of the Report. IMPORTANT NOTICE (I) The Board, the Supervisory Committee and the Directors, Sup
3、ervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of quarterly reports, and that there are no false representations, misleading statements or material omissions contained in the Report, and severally and jointly accept responsibi
4、lity. (II) The person-in-charge of the Company, the person-in-charge of the Companys accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial statements contained in quart
5、erly reports. (III) Whether the first quarterly financial statements are audited Applicable N/A (IV) The Report is prepared in both Chinese and English. In case of any ambiguity in the understanding of the Chinese and English texts, the Chinese version shall prevail. I Principal Financial Data (I) P
6、rincipal accounting data and financial indicators Unit: Yuan Currency: RMB Item The Reporting Period: (January-March 2022) Year-on-Year Change (%) Revenues 4,657,343,538.89 12.36 Net profit attributable to Shareholders of the listed company 460,537,813.53 25.52 Net profit attributable to Shareholder
7、s of the listed company after deducting the extraordinary gain or loss 457,193,702.95 36.47 Net cash flow from operating activities 871,904,476.98 76.27 Basic earnings per share (RMB/share) 0.2411 28.49 Diluted earnings per share (RMB/share) 0.2410 28.72 Weighted average return on net assets (%) 3.8
8、4 Increased by 0.58 percentage points Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report 2 / 16 End of the Reporting Period End of the Previous Year Change from the end of the previous year to the end of the Reporting Period (%) Total assets 32,275,092,753.15 31,103,900,389
9、.29 3.77 Owners equity attributable to Shareholders of the listed company 12,073,975,596.59 11,820,293,656.69 2.15 Note: During the Reporting Period, the Company recorded revenues of RMB 4,657 million, representing an increase of 12.36% year-on-year; the main driver of the growth is steady increasin
10、g sales volume of main product categories in key specialist arenas. During the first quarter of 2022, Revenues from chemical drug preparation products amounted to RMB 2,737 million, representing an increase of 24.54% year-on-year, of which, Revenues from Inhalation products amounted to 363 million,
11、representing an increase of 324.90% year-on-year; Revenues from anti-infective drugs amounted to RMB 350 million, representing an increase of 26.91% year-on-year; Revenues from gastroenterology products amounted to RMB 1,070 million, representing an increase of 5.90% year-on-year; Revenues from gona
12、dotropic hormones products amounted to RMB 737 million, representing an increase of 22.84% year-on-year; Revenues from APIs and intermediates amounted to RMB 1,406 million, representing an increase of 14.90% year-on-year. The Revenues from traditional Chinese medicine preparations amounted to RMB 28
13、3 million, representing a decrease of 33.53% year-on-year. The Revenues from diagnostic reagents and equipment products amounted to RMB162 million, representing a decrease of 30.77% year-on-year. (II) Items and amounts of extraordinary gains and losses Unit: Yuan Currency: RMB Item Amounts for the R
14、eporting Period Explanation Gains and losses on disposal of non-current assets -374,417.51 Proceeds from disposal of fixed assets Government grants included in profit and loss for the Period (except for government grants closely associated with normal corporate businesses, entitled at fixed amount o
15、r fixed level according to national policies and national unified standards) 56,644,887.24 Government grants through the profits and losses for the Period Gains and losses on fair value changes derived from holding of financial assets held for trading, derivative financial assets, financial liabilit
16、ies held for trading, derivative financial liabilities, and investment income generated on disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except for effective hedging act
17、ivities related to the ordinary operating business of the Company -45,275,532.62 Gains or losses arising from changes in fair value of financial assets/liabilities held for trading, and investment gains from holding and disposal of financial assets/liabilities held for trading Other non-operating Re
18、venues and non-operating expenditures apart from the above items 241,415.42 Other non-operating Revenues and non-operating expenditures apart from the above items Less: Income tax effect 9,124,665.76 Effect of the above items on income tax Effect of minority interests after tax -1,232,423.81 The por
19、tion of the above items to which minority shareholders are entitled Total 3,344,110.58 Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report 3 / 16 The explanation on the recognitions of the items of extraordinary gains and losses as set out in the “Interpretative Announcement
20、 for Information Disclosure of Companies that Issue Securities to the Public No. 1 Extraordinary Gains or Losses” as items of recurring gains and losses Applicable N/A (III) Changes and the reasons for changes in principal accounting data and financial indicators Applicable N/A Name of item Change i
21、n proportion（%） Explanation Net profit attributable to Shareholders of the listed company after deducting the extraordinary gain or loss 36.47 Mainly due to the growth of the sales revenues from the chemical drugs and APIs products, which is the main driver of the growth of the net incomes. Net cash
22、 flow from operating activities 76.27 Mainly due to an increase of cash collections of sales revenues. （IV）Substantial changes of other items in the Financial Statements and financial indicators and reasons thereof Unit: Yuan Currency: RMB Balance Sheet 2022/03/31 2021/12/31 Change in proportion （%）
23、 Main Reason Short-term loans 1,655,807,901.10 2,518,484,835.09 -34.25 Mainly due to repayment of loans in the Period. Contract liabilities 124,089,632.31 234,140,702.29 -47.00 Mainly due to part of the contract payments received in advance in the Period which met the conditions for revenue recognit
24、ion were transferred to revenues. Taxes payables 382,548,978.08 270,618,183.41 41.36 Mainly due to an increase in enterprise income tax payables. Long-term loans 1,816,661,809.48 826,780,252.78 119.73 Mainly due to an increase of new long-term loans by subsidiaries in the Period. Treasury shares 472
25、,590,296.96 222,644,454.50 112.26 Mainly due to the share repurchased during the current period. Other comprehensive income -87,498,451.08 5,387,545.97 -1724.09 Mainly due to the disposal of stocks of China Galaxy Securities Co., Ltd. held during the Period. Income Statement 2022 Jan.-Mar. 2021 Jan.
26、-Mar. Change in proportion （%） Main Reason Investment incomes 29,176,808.52 21,812,732.70 33.76 Mainly due to the increase in the investment incomes from associate investments held in the current period. Gains from changes in fair value -54,151,999.18 -39,393,074.92 N/A Mainly due to fluctuations in
27、 the market value of subject securities investment held. Credit impairment loss 217,773.10 -3,611,272.93 N/A Mainly due to the recovery of the accounts receivables with relatively long ages in the current period which offset the expected credit losses accrued in the previous period. Asset impairment
28、 loss -5,309,013.21 -22,802,167.34 N/A Mainly due to a decrease in the provision for inventory depreciation in the current period as compared with the previous period. Gains from disposal of assets -370,357.71 21,927.78 -1788.99 Mainly due to losses occurred from disposal of fixed assets in the curr
29、ent period. Non-operating income 2,321,933.96 24,072,371.67 -90.35 Mainly due to the land disposal in the previous period. Non-operating expenditure 2,084,578.34 3,257,611.14 -36.01 Mainly due to larger non-profit donation expenditure in the previous period. Other comprehensive net income after taxa
30、tion -106,847,774.60 -166,618,134.73 N/A Mainly due to changes in the fair value of other equity instrument investments. Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report 4 / 16 Cash Flow Statement 2022 Jan.-Mar. 2021 Jan.-Mar. Change in proportion （%） Main Reason Net cash
31、 flow from operating activities 871,904,476.98 494,649,514.25 76.27 Mainly due to an increase of cash collections of sales revenues. Net cash flow from investment activities -77,907,837.67 -269,420,918.38 N/A Mainly due to the increase in cash inflow from investing activities caused by the disposal
32、of stocks of China Galaxy Securities Co., Ltd. held during the Period. Net cash flow from financing activities 62,714,553.34 -542,754,908.85 N/A Mainly due to an increase of new long-term loans in the current period. Effect of changes in foreign exchange rates on cash and cash equivalents -12,259,20
33、1.98 3,666,733.44 -434.34 Mainly due to an increase of exchange losses on foreign currency funds held as a result of the fluctuations in exchange rates. Net increase in cash and cash equivalents 844,451,990.66 -313,859,579.54 N/A Mainly due to an increase of cash from daily operating activities of t
34、he Company and an increase of new long-term loans. II Shareholders Information (I) Table of the total number of ordinary shareholders, the number of preferred shareholders with resumed voting rights and shareholdings of the top 10 shareholders Unit: Shares Total number of ordinary shareholders at th
35、e end of the Reporting Period 102,434 Total number of preferred shareholders with resumed voting rights at the end of the Reporting Period (if any) 0 Shareholdings of the top 10 shareholders Name of shareholders Nature of shareholders Number of shares Percentage (%) Number of shares held with sellin
36、g restrictions Pledge, mark or lock-up Share status Number Shenzhen Baiyeyuan Investment Co., Ltd. * (深圳市百业源投资有限公司) Domestic non-state-owned legal person 895,653,653 46.85 0 Pledge 95,679,725 Hong Kong Securities Clearing Company Limited Unknown 127,833,815 6.69 0 Unknown Might Seasons Limited Overs
37、eas legal person 57,487,434 3.01 0 Unknown 108 portfolio of national social security fund Unknown 11,461,721 0.60 0 Unknown Huaxia Life Insurance Co., Ltd. - proprietary fund Unknown 9,275,718 0.49 0 Unknown 16011 portfolio of basic endowment insurance fund Unknown 9,050,234 0.47 0 Unknown Bosera Fu
38、nds Management Co., Ltd. - 419 portfolio of social security funds Unknown 8,732,946 0.46 0 Unknown He Zhong Domestic natural person 7,800,024 0.41 0 Unknown Abu Dhabi Investment Authority Overseas legal person 5,417,816 0.28 0 Unknown Agricultural Bank of China Limited - China 500 Exchange Traded Op
39、en-End Index Securities Investment Fund (ETF) Unknown 4,690,194 0.25 0 Unknown Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report 5 / 16 Shareholdings of the top 10 shareholders without selling restrictions Name of shareholders Number of tradable shares held without selling
40、 restrictions Class and number of shares Class Class Shenzhen Baiyeyuan Investment Co., Ltd. * (深圳市百业源投资有限公司) 895,653,653 Ordinary shares denominated in Renminbi 895,653,653 Hong Kong Securities Clearing Company Limited 127,833,815 Ordinary shares denominated in Renminbi 127,833,815 Might Seasons Li
41、mited 57,487,434 Ordinary shares denominated in Renminbi 57,487,434 108 portfolio of national social security fund 11,461,721 Ordinary shares denominated in Renminbi 11,461,721 Huaxia Life Insurance Co., Ltd. - proprietary fund 9,275,718 Ordinary shares denominated in Renminbi 9,275,718 16011 portfo
42、lio of basic endowment insurance fund 9,050,234 Ordinary shares denominated in Renminbi 9,050,234 Bosera Funds Management Co., Ltd. - 419 portfolio of social security funds 8,732,946 Ordinary shares denominated in Renminbi 8,732,946 He Zhong 7,800,024 Ordinary shares denominated in Renminbi 7,800,02
43、4 Abu Dhabi Investment Authority 5,417,816 Ordinary shares denominated in Renminbi 5,417,816 Agricultural Bank of China Limited - China 500 Exchange Traded Open-End Index Securities Investment Fund (ETF) 4,690,194 Ordinary shares denominated in Renminbi 4,690,194 Description of connection or acting-
44、in-concert relationship of the above shareholders There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co., Ltd., the controlling shareholder of the Company, and other shareholders; whether there is connection or acting-in-concert relationship among other s
45、hareholders is unknown. Description of the participation of the top 10 shareholders and the top 10 shareholders without selling restriction in securities margin trading and securities financing (if any) Shareholder He Zhong held 800,000 shares through an ordinary securities account and 7,000,024 sha
46、res through a customers margin account, namely 7,800,024 shares in total. Notes on the special repurchase account among the top 10 shareholders As at the end of the Reporting Period, the special repurchase account of the Company (special securities repurchase account of Joincare Pharmaceutical Group
47、 Industry Co., Ltd.) owned 38,402,584 shares in total, accounting for 2.01% of total share capital of the Company. III Other Information Other key information on the operations of the Company during the Reporting Period to which investors should be reminded to pay attention Applicable N/A 1.Use of p
48、roceeds Pursuant to the “Resolution on Change of Certain Projects Invested with Proceeds” considered and approved at the 8th meeting of the 8th Session of the Board of the Company on 24 January 2022, it was agreed that Zhuhai Health Industry Base Construction Project was changed to the New Product R
49、&D Project, Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion Project and the Information Platform Construction Project. The resolution was approved at the 2022 1st extraordinary general meeting of the Company on 11 February 2022. Before the alteration of the projects invested w
50、ith the Proceeds is as follows: Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report 6 / 16 Unit: 10,000 Yuan Project name Total amount of investment Total amount of proceeds investment Use of proceeds as at 31 December 2021 Balance of proceeds as at 31 December 2021 Zhuhai H